{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T02:32:08Z","timestamp":1769308328745,"version":"3.49.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00478","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T09:21:34Z","timestamp":1559812894000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Granulomatosis With Polyangiitis in a Patient on Programmed Death-1 Inhibitor for Advanced Non-small-cell Lung Cancer"],"prefix":"10.3389","volume":"9","author":[{"given":"Anne","family":"Sibille","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Malaise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Detrembleur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Pirotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Louis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Duysinx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer."},{"key":"B3","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/j.1600-0560.2006.00699.x","article-title":"Cutaneous manifestations of Wegener's granulomatosis: a clinicopathologic study of 17 patients and correlation to antineutrophil cytoplasmic antibody status","volume":"34","author":"Comfere","year":"2007","journal-title":"J Cutan Pathol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1056\/NEJMc1801663","article-title":"Adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e1231292","DOI":"10.1080\/2162402X.2016.1231292","article-title":"Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer","volume":"5","author":"Hasan Ali","year":"2016","journal-title":"Oncoimmunology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1001\/archderm.131.3.314","article-title":"Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells","volume":"131","author":"Cui","year":"1995","journal-title":"Arch Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/ITT.S126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review","volume":"6","author":"Yoest","year":"2017","journal-title":"Immunotar Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.intimp.2018.10.045","article-title":"PD-1 blockade augments humoral immunity through ICOS-mediated CD4","volume":"66","author":"Zhang","year":"2019","journal-title":"Int Immunopharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0715","article-title":"Sarcoid-like granulomatosis of the lung related to immune-checkpoint inhibitors: distinct clinical and imaging features of a unique immune-related adverse event","volume":"6","author":"Nishino","year":"2018","journal-title":"Cancer Immunol Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.rmr.2018.08.003","article-title":"Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors","volume":"35","author":"Faviez","year":"2018","journal-title":"Rev Mal Respir."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/rheumatology\/kew063","article-title":"Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition","volume":"55","author":"van den Brom","year":"2016","journal-title":"Rheumatology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/rheumatology\/kes034","article-title":"Aberrant expression of the negative costimulator PD-1 on T cells in granulomatosis with polyangiitis","volume":"51","author":"Wilde","year":"2012","journal-title":"Rheumatology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1479-5876-7-35","article-title":"CTLA4 blockade increases Th17 cells in patients with metastatic melanoma","volume":"7","author":"von Euw","year":"2009","journal-title":"J Transl Med."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00478\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T09:21:35Z","timestamp":1559812895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00478\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,6]]},"references-count":21,"alternative-id":["10.3389\/fonc.2019.00478"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00478","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,6]]},"article-number":"478"}}